Back HIV/AIDS

HIV / AIDS

IAS 2013: Lower-dose Efavirenz as Effective as Standard Dose [VIDEO]

Lowering the dosage of efavirenz (Sustiva) from 600 mg to 400 mg did not compromise its effectiveness, according to data from the ENCORE1 study presented at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this week in Kuala Lumpur.

alt

IAS 2013: Early Testing and Treatment Linked to Lower Sexual Risk in Thai Study [VIDEO]

Gay men who started antiretroviral treatment during acute HIV infection achieved good viral load suppression in both blood and semen, and also reported reduced sexual risk behavior, researchers reported at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this week in Kuala Lumpur.

alt

HIV Treatment Highlights from IAS 2013 [VIDEO]

Cal Cohen offers a summary of some of the major studies of antiretroviral treatment strategies presented at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) last week in Kuala Lumpur.alt

IAS 2013: Studies Look at Second-Line Bone Changes, Fractures, and HIV- and HCV-Related Bone Loss

People with HIV experience less bone loss if they switch to a NRTI-sparing second-line regimen containing raltegravir, researchers reported last week at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this week in Kuala Lumpur. Other studies showed that HIV infection is associated with increased risk of hip fractures and shed light on different mechanisms of bone loss associated with HIV and hepatitis C.

alt

IAS 2013: Second-line HIV Therapy with NRTIs Linked to Bone Loss [VIDEO]

Bone loss occurs less often when people on failing antiretroviral therapy switch to a NRTI-sparing second-line regimen containing raltegravir, researchers reported last week at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this week in Kuala Lumpur.

alt

IAS 2013: No Increase in Risk Behavior among People Taking ART, Meta-Analysis Shows

One of the anxieties in relation to treatment as prevention is that it may discourage people with HIV from using condoms and other prevention methods. However, a meta-analysis has found no increase in risk-taking among people taking antiretroviral treatment, researchers reported at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this week in Kuala Lumpur last week.

alt

IAS 2013: Switch to Etravirine Maintains Viral Suppression and Improves Lipid Levels

People with HIV who switch from their current antiretroviral regimen to the NNRTI etravirine (Intelence) maintain undetectable viral load and may see improvement in metabolic parameters, according to a report presented at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this week in Kuala Lumpur.alt